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Abstract 
Background: Multidrug resistance-associated protein 1 (MRP1) overexpression plays a major role in chemoresistance 
in glioblastoma multiforme (GBM) contributing to its notorious deadly nature. Although MRP1-siRNA transfection to 
GBM in vitro has been shown to sensitise the cells to drug, MRP1 silencing in vivo and the phenotypic influence on 
the tumour and normal tissues upon MRP1 down-regulation have not been established. Here, porous silicon nano-
particles (pSiNPs) that enable high-capacity loading and delivery of siRNA are applied in vitro and in vivo.
Result: We established pSiNPs with polyethyleneimine (PEI) capping that enables high-capacity loading of siRNA 
(92 µg of siRNA/mg PEI-pSiNPs), and optimised release profile (70% released between 24 and 48 h). These pSiNPs are 
biocompatible, and demonstrate cellular uptake and effective knockdown of MRP1 expression in GBM by 30%. Also, 
siRNA delivery was found to significantly reduce GBM proliferation as an associated effect. This effect is likely mediated 
by the attenuation of MRP1 transmembrane transport, followed by cell cycle arrest. MRP1 silencing in GBM tumour 
using MRP1-siRNA loaded pSiNPs was demonstrated in mice (82% reduction at the protein level 48 h post-injection), 
and it also produced antiproliferative effect in GBM by reducing the population of proliferative cells. These results 
indicate that in vitro observations are translatable in vivo. No histopathological signs of acute damage were observed 
in other MRP1-expressing organs despite collateral downregulations.
Conclusions: This study proposes the potential of efficient MRP1-siRNA delivery by using PEI-capped pSiNPs in 
achieving a dual therapeutic role of directly attenuating the growth of GBM while sensitising residual tumour cells to 
the effects of chemotherapy post-resection.
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Background
Glioblastoma multiforme (GBM) is a deadly form of 
brain cancer with only a 5% survival rate at 5  years [1] 
and the age-standardised mortality rate of brain cancer 
in 2012 remains the same as in 1982 [2]. The mainstay of 
therapy is surgical resection. Factors that contribute to 
the deadly nature of this cancer include the invasiveness 
of GBM cells, and therefore residual disease, at the resec-
tion margins; the selective permeability of the blood–
brain barrier (BBB), and the inherent chemoresistance in 
the endothelial layer at the BBB and in the GBM cells [3, 
4]. As the drug fails to penetrate and accumulate, it leads 
to poor chemotherapy effectiveness in both consolidation 
and treatment of unresectable tumours.
Open Access
Journal of Nanobiotechnology
*Correspondence:  Bryone.Kuss@sa.gov.au; nicolas.voelcker@monash.edu 
1 Monash Institute of Pharmaceutical Sciences, Monash University, 381 
Royal Parade, Parkville, VIC 3052, Australia4 School of Medicine, Flinders 
University, Bedford Park, Adelaide, SA 5042, Australia
Full list of author information is available at the end of the article
Page 2 of 17Tong et al. J Nanobiotechnol  (2018) 16:38 
Chemoresistance results from the expression of mem-
brane-bound efflux transporters, such as the multidrug 
resistance protein (MRP) superfamily [5]. Multidrug 
resistance-associated protein 1 (MRP1), a MRP sub-
type, is a 190 kDa protein, through the hydrolysis of ATP, 
it actively removes substrates from cytoplasm [6]. It’s 
overexpression in certain tumours removes drugs from 
cancer cells compromising treatment effectiveness [7]. 
Conventional drugs for GBM treatment, such as temo-
zolomide (TMZ) and vincristine (VCR), are substrates of 
MRP1 which is overexpressed in brain tumours [8] and 
on the apical surface of endothelial cells of the BBB [9]. 
These drugs are transported out of the tumour and out 
of the intracranial space, contributing significantly to the 
multidrug resistant phenotype of GBM.
Inhibition of MRP1 is a strategy for chemosensitisa-
tion and this approach has been substantiated in lung 
carcinoma in vitro and in vivo [10]. Small molecules are 
discovered to target and attenuate MRP1 function in 
various carcinomas over the last decade [11–13]. In com-
parison, small interfering RNA (siRNA) are more eco-
nomical, versatile and effective in specific knockdown 
of protein [14], however its susceptibility to degradation 
and incapability in penetrating cell plasma membrane are 
the main obstacles for translation into clinical practice 
[15]. Nanoparticle delivery is a way to overcome those 
pharmacokinetic limitations, in which we demonstrated 
the use of bare porous silicon nanoparticles (pSiNPs) to 
deliver siRNA into cells [16]. In particular, pSiNPs were 
used as the delivery vehicle due to their high biocom-
patibility and degradability, and their degradation prod-
uct, silicic acid, is non-toxic and is cleared rapidly [17, 
18]. The high porosity and surface area of pSiNPs ena-
bles high concentrations of therapeutics to be delivered 
per weight of pSiNP [19, 20]. These pSiNPs have been 
employed in drug delivery applications such as delivery 
of enzymes [21], small molecules [22], and nucleotides 
[23]. The release of the drug can be easily tailored by con-
trolling the degradation rate of pSiNPs and their surface 
chemistry [24, 25]. Thermal hydrocarbonisation (THC) 
treatment is a well-established modification to improve 
the hydrolytic stability of pSiNPs [26–28]. Owing to the 
polyanionic nature of siRNA, cationic surface treatments 
are believed to be more favourable to retain siRNA inside 
pSiNP [29].
MRP1 knockdown in GBM cells in  vitro using vari-
ous polymeric vectors as transfection method has sug-
gested that such anti-chemoresistance approach is viable, 
however, the inhibition of MRP1 in GBM tumours has 
not yet been established. Moreover, the side-effect of 
MRP1 knockdown on phenotypes of GBM cells and on 
other MRP1-expressing cells has not yet been investi-
gated. Here, we studied the extend of MRP1 silencing 
and associated effects using siRNA delivered in pSiNPs 
with PEI optimised capping to control its release, and 
also report the effect and mechanism of this on the inhi-
bition of proliferation of GBM cells in vitro and in vivo. 
At the same time, we also evaluated the side effects of 
MRP1 silencing in the organs that the nanoparticles may 
accumulate in. We anticipate that the results will provide 
insights into the potential of MRP1 gene therapy in GBM 
treatment, and unlock the door to eradication of this fatal 
disease.
Methods
Porous silicon nanoparticle (pSiNP) fabrication
pSiNPs were fabricated according to the previously 
reported procedure [23, 27] from p+ type (0.01–
0.02  Ω  cm) silicon wafers (Siegert Consulting Co., 
Aachen, Germany) by periodically etching at 50 (2.2  s 
period) and 200 (0.35 s period) mA/cm2 in a solution of 
1:1 hydrofluoric acid (38%):ethanol (EtOH) for 20  min. 
Afterwards, the porous silicon (pSi) films were detached 
from the substrate by abruptly increasing the current 
density to electropolishing conditions (250  mA/cm2, 
3 s period). The detached multilayer pSi films were then 
thermally hydrocarbonised under  N2/acetylene (1:1, vol.) 
flow at 500 °C for 15 min, and cooled down to room tem-
perature under a stream  N2 gas. Subsequently, pSiNPs 
were produced by wet ball-milling  (ZrO2 grinding jar, 
Pulverisette 7, Fritsch GmbH, Idar-Oberstein, Germany) 
of the thermally hydrocarbonised pSi films in 1-decene. 
The completion of THC surface treatment was confirmed 
by FTIR analysis via the disappearance of Si-Hx species 
(2200  cm−1) and strong signal corresponding to C–H 
(3000  cm−1) and Si–C (770  cm−1) species (Additional 
file  1: Figure S1). pSiNPs were harvested by centrifuga-
tion (1500×g, 5  min). pSiNP stock solutions were pre-
pared in EtOH at 20 mg/ml.
siRNA loading, PEI capping and release kinetics
After pSiNP fabrication and characterisation, siRNA 
was loaded and particles were coated with polyether-
imine (PEI). Both test siRNA (siRNA) and scramble 
siRNA (ctrl siRNA) were purchased from GenePharma 
Co. Ltd. (Shanghai, China). siRNA is complementary to 
mRNA sequence encoding for MRP1 (5′ GAGGCUUUG 
AUCGUCAAGUTT 3′), while ctrl siRNA sequence (5′ 
UUCUCCGAACGUGUCACGUTT 3′), lacks homol-
ogy to all other genes. These siRNAs were solubilised in 
molecular biology grade water to make stock solutions 
(500 µg/ml). siRNA loading was performed by our previ-
ously established protocol [23]. Briefly, siRNA (100 µl of 
500 µg/ml in water) was added to pSiNPs (250 µl of 1 mg/
ml in EtOH), mixed by sonication for 1 min, then incu-
bated overnight at 4  °C. Following the incubation, the 
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loaded pSiNPs were isolated by centrifugation at 5000 rcf 
at 4  °C then resuspended in EtOH and centrifuged two 
more times to wash off unbound siRNA. To cap the 
siRNA loaded pSiNPs with PEI, the pellet was then resus-
pended in 0.05% PEI of 25 kDa (Sigma-Aldrich, 408727) 
diluted in EtOH and incubated for 20 min. pSiNPs were 
centrifuged, and the pellet was washed with EtOH for 
three times to wash off excess PEI.
To measure the loading efficiency of siRNA into 
pSiNPs, siRNA concentration in the supernatant was 
measured at 260  nm by using a Nanodrop spectropho-
tometer (ND2000, ThermoFisher) and the amount of 
siRNA was then back calculated. The loading efficiency 
(%) = (the siRNA amount in loading buffer − the siRNA 
amount in supernatant)/(the siRNA amount in loading 
buffer) × 100%.
The release kinetics were determined by incubat-
ing PEI-pSiNPs/siRNA (MRP1 and ctrl) in PBS at 37  °C 
for 120  h. The supernatant was extracted at designated 
time points, and the amount released was back calcu-
lated from the absorbance measurement at 260 nm. The 
in  vitro and in  vivo treatment schedule was based on 
the release kinetics. The reason for conducting release 
kinetic assay in PBS, instead of culture medium is that 
quantitating siRNA released in protein containing 
medium is problematic owing to the masking of the RNA 
absorbance at 260 nm. Quantitation in PBS is reliable and 
its physiological relevant pH and osmolality are suitable 
for demonstrating the siRNA release from PEI-capped 
pSiNP.
To compare the siRNA knockdown efficacy and to 
delineate the cell phenotypes influenced by the nano-
particle of choice, lipofectamine (Invitrogen, 11668-019) 
was used in parallel as a delivery agent. The loading of 
siRNA to form a siRNA-lipid complex with lipofectamine 
was performed following the supplier’s protocol. Briefly, 
siRNA was first diluted in Opti-MEM (Gibco, 51985091). 
It was then mixed with lipofectamine at a 1:1 ratio to 
form siRNA-lipid complex. All siRNA loadings were car-
ried out immediately prior to cell exposure under sterile 
conditions.
Size and zeta‑potential characterisation of pSiNPs
To reveal the size distribution and zeta-potential of 
pSiNPs, the particles were first washed and resuspended 
into MilliQ and sonicated for 5 min. The particles were 
then analysed using a Zetasizer Nano ZS (Malvern, 
Worcestershire, UK). The analysis was carried out at a 
scattering angle of 90° at a temperature of 25 °C.
TEM characterisation
Transmission electron microscopy (TEM) was done 
to visually examine the size and structure of pSiNPs 
prepared. pSiNP stock solution was first sonicated to 
homogenise particles. PEI-pSiNPs and pSiNPs without 
coating, siRNA-loaded or empty were diluted in EtOH. 
10 µl of solution was spotted onto each 300 mesh Cu grid 
(ProSciTech Co.) and air-dried. The samples were then 
observed under a field-emission TEM (JEOL, JEM-2100F, 
Japan). The average pore size of pSiNP was determined 
firstly by SEM imaging freshly etched pSi film before 
detachment and ball milling. TEM images was taken 
to further confirm the pore size by measuring pores of 
pSiNP. The pore diameter is determined by measuring 
wall-to-wall distance of individual pores using ImageJ. 
The average was taken from 50 measurements of ran-
domly selected particles.
Cell culture
In this study we used U87 cells of human origin that sta-
bly express cytoplasmic mCherry, a kind gift from Bak-
hos A. Tannous, MGH, Massachusetts, USA, and T98G 
cells of human origin  (ATCC®  CRL-1690™). Both are 
well-recognised model cell lines representing GBM, 
mCherry expressing GBM cells allow live cell imaging of 
nanoparticle uptake. It is documented that both cell lines 
demonstrate a similar cell growth rate [30]. Cell lines 
were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM, Sigma-Aldrich D6546) supplemented with 10% 
foetal bovine serum (Invitrogen), 1% antibiotic–anti-
mycotic (Invitrogen) at 37  °C and 5%  CO2 in a humidi-
fied incubator. For lipofectamine-based siRNA delivery, 
Opti-MEM reduced serum medium was used in culture. 
For tumour xenograft inoculation preparation, 10  mM 
HEPES buffer (Sigma-Aldrich, H0887) was supplemented 
in DMEM for stabilising the pH of high confluence cul-
ture. All experiments were conducted following at least 
two passages after thawing cells.
For the functional inhibition assay, MK-571, the MRP1 
inhibitor (a leukotriene receptor ligand), was used to 
determine the functional activity of MRP1 in T98G GBM 
cell line, followed by a Calcein-AM (Santa Cruz Bio-
technology, Inc., Dallas, TX, USA) accumulation assay 
[31]. Calcein AM was used to measure the multidrug 
transporter-mediated activity. It is a non-fluorescent 
probe, but when it permeates the cells, it hydrolyses to 
a fluorescent molecule. Cells were seeded at 3 × 105 
cells/well in 6 well-plates and allowed to adhere over-
night. Subsequently, a total of 25 µM MK-571 was added 
to each well and incubated for a further 72  h. The cells 
were analysed at 24, 48, 72  h. At the 24  h time point, 
cells were incubated with 0.20 µM of Calcein AM stain-
ing solution at 37  °C. After incubation for 30  min, cell 
samples were immediately washed and analysed by 
Accuri-C6 flow cytometer (BD Accuri Cytometers Inc., 
USA) to determine cellular uptake of Calcein AM. The 
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control experiment was performed under identical con-
ditions. 1 × 104 events were collected by flow cytometry. 
Cell viability was measured by trypan blue and Annexin 
V as described previously [32].
The cells were seeded into 6-well plates at a density 
of 5 × 104 cells/cm2 and maintained in DMEM for 24  h 
after which the cultured cells were exposed to sterilised 
pSiNPs (bare/capped with PEI/loaded with siRNA) at a 
concentration of 0.125 mg/ml (250 µl per well of 1 mg/
ml) for 24  h. After 24  h, cells were washed with sterile 
PBS and a second dose of pSiNPs was added (0.125 mg/
ml) for another 24 h, followed by cells washed with sterile 
PBS then maintained in DMEM for another 24 h before 
harvesting for different studies.
Cellular uptake of pSiNPs
To visualise the uptake of pSiNPs in U87 cells, nano-
particles fabricated as described above, were fluores-
cently labelled with fluorescein-5-thiosemicarbazide. 
pSiNPs were first hydrosilylated to obtain an acti-
vated carboxyl group on the surface by incubating with 
neat undecylenic acid (UA) for 16 h at 120  °C [33]. The 
pSiNPs were extracted from UA via centrifugation 
after the reaction and washed with EtOH five times to 
ensure complete removal of excess UA. Next, the car-
boxy-functional pSiNP surface was covalently modified 
with fluorescein-5-thiosemicarbazide dye by means of 
ethyl(dimethylaminopropyl)carbodiimide (EDC)/N-
hydroxysuccinimide (NHS) coupling reaction. EtOH was 
removed from UA-functionalised pSiNPs by centrifuga-
tion and the particles were rinsed with DMF twice. An 
8 mM solution of EDC in anhydrous DMF was prepared 
and 0.2 equivalents of triethylamine were added to the 
solution. In the meantime, 8  mM solution of NHS was 
prepared in anhydrous DMF. 500 µl of each solution was 
removed, mixed well and added to the UA-functionalised 
pSiNPs, followed by addition of 1 ml of fluorescein-5-thi-
osemicarbazide solution (4  mM). The entire reaction 
mixture was allowed to react for 24 h at RT in the dark 
with stirring. Excess cross linking agent, dye and DMF 
were removed by centrifugation and the nanoparticles 
were copiously washed with cold water, followed by an 
EtOH wash and stored in EtOH. An alternative of track-
ing the subcellular delivery of siRNA is by loading pSiNP 
with FAM-labelled siRNA. However, this is not reported 
here since the change of physical/chemical properties 
of siRNA and the resulting changes in release profile is 
unknown.
After fluorescence labelling, pSiNPs were either 
coated with PEI as described above, or left uncoated. 
The zeta-potential, hydrodynamic size and release pro-
file of fluorescence labelled pSiNPs/PEI capped pSiNP 
were unaltered. U87 cells were then exposed to these 
particles for 3  h, then washed three times with warm 
PBS to remove excess pSiNPs. Cells were cultured for 
another 24  h before fixation, counterstained, mounted 
and imaged under a confocal microscope (ELYRA super-
resolution microscope, Zeiss Elyra PS.1).
Trypan Blue viability assay
A Trypan Blue exclusion assay was performed to study 
the effect of PEI-pSiNP delivery on the viability of cells. 
Briefly, U87 cells exposed to PEI capped or bare pSiNPs 
were washed, trypsinised, diluted, and mixed 1:1 with 
sterile filtered 0.4% Trypan Blue solution (T8154, Sigma). 
After 5  min incubation, cells were counted using a 
haemocytometer under a bright field microscope. The 
proportion of the viable cells to total cells are reported.
EdU assay of cells
The proliferation rate of U87 cells receiving siRNA 
delivery by lipofectamine or PEI-pSiNPs, and respec-
tive controls were assessed through pulse labelling of 
cells using the Click-iT EdU Imaging Kit (Invitrogen, 
C10337). Briefly, cells were seeded on the poly-l-lysine 
coated coverslips at a density of 5 × 104 cells/cm2. At 24 h 
post exposure, cells were incubated with 10 mM of EdU 
(5-ethynyl-2-deoxyuridine) in DMEM for 1 h. Cells were 
then washed and fixed in 4% PFA and permeabilised in 
0.5% Triton X-100 in PBS. S-phase cells, which are EdU 
positive, were visualised following the protocol specified 
by the manufacturer. All cells were counter-stained  by 
Hoechst 33342, and mounted on a glass slide with fluo-
rescence mounting medium (Dako, S3023). Images were 
taken under widefield Olympus IX83 fluorescence micro-
scope using a 10× objective. Image analysis was done 
using Fiji ImageJ v.2.0.0. to automatically count nuclei 
with positive staining. The averaged ratio of EdU positive 
nuclei to the total number of cells is reported as “EdU 
positive nuclei proportion (%)”. This directly reflects the 
proliferation rate of cells.
Immunofluorescence
The cells were seeded onto poly-l-lysine coated glass 
coverslips, in a 6-well plate, at the cell density described, 
and were exposed to PEI-pSiNPs with or without siRNA, 
or lipofectamine carrying siRNA, or left untreated. After 
24  h, cells were fixed for 10  min with 4% freshly pre-
pared PFA at room temperature, quenched with 100 mM 
glycine in PBS for 15  min and washed twice with PBS 
before permeabilisation in 0.05% Triton X-100 in PBS 
for 5  min at room temperature. After permeabilisation, 
the cells were washed twice with PBS and blocked with 
3% bovine serum albumin (BSA) in PBS for 30  min at 
room temperature. The cells were then incubated with 
primary antibodies overnight, washed, and incubated 
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with fluorochrome-conjugated secondary antibodies 
for 60  min. The slides were washed in PBS then coun-
terstained for 15  min. The primary antibody used was 
mouse anti-ki67 (Abcam, ab8191). The secondary anti-
body used was Alexa 488 goat anti-mouse (Invitrogen, 
A11001). Rhodamine-phalloidin (Invitrogen, R415) and 
Hoechst (Sigma-Aldrich, B2261) were used to counter 
label the actin filaments and nuclei, respectively. After 
washing, cells on coverslips were mounted on a glass 
slide. These samples were then imaged at high magnifi-
cation using a confocal microscope (ELYRA Superresolu-
tion Microscope, Zeiss Elyra PS.1).
For statistical analysis, images were taken under a 
widefield Olympus IX83 fluorescence microscope, and 
counted using the image analysis technique described 
above. The averaged ratio of ki67 positive nuclei to the 
total number of nuclei was calculated, directly indicating 
the progression of the cell cycle.
Western blotting
To study the relative protein expression of MRP1 and cell 
cycle checkpoints, protein lysates were analysed by West-
ern blotting. The cells that were exposed to PEI-pSiNPs 
with MRP1 siRNA or control siRNA, or siRNA delivered 
in lipofectamine, or left untreated were washed in warm 
PBS and directly lysed in a sodium dodecyl sulphate (SDS) 
lysis buffer (2% SDS, 50 mM Tris pH 6.8) supplemented 
with protease inhibitor cocktail (Sigma, P8340). Tissue 
samples were thawed and homogenised using Navy Bead 
Lysis Kits using a tissue homogeniser (Bullet Blender, 
BB24-AU). The protein concentration was quantified by 
an EZQ protein quantitation kit (Invitrogen, R3320). The 
proteins were then mixed with Laemmli loading buffer 
(BioRad, 161-0747) with β-mercaptoethanol, and boiled 
at 95 °C for 10 min. To analyse MRP1, proteins were elec-
trophoresed in 10% bis-acrylamide gels, and transferred 
onto nitrocellulose membranes overnight. For pCdk2 and 
pHistone H3 analysis, electrophoresis was performed 
with 14% bis-acrylamide gel. Membranes were blocked 
with 5% (w/v) non-fat milk powder (Devondale) in PBST 
(0.05% Tween-20 in PBS) for 60 min, followed by wash-
ing with PBST and incubation with a primary antibody 
in blocking buffer overnight with rocking at 4  °C. The 
primary antibodies used were mouse anti-MRP1, rabbit 
anti-Cdk2 pTyr15, and rabbit anti-Histone H3 pSer10 
(Abcam, ab24102 and ab136810, respectively). The sec-
ondary antibodies used were horseradish peroxidase con-
jugated Immun-Star goat anti-mouse immunoglobulin G 
(BioRad, 1705047) and goat anti-rabbit immunoglobulin 
G (Agrisera, AS09602). The membranes were washed 
and incubated with the secondary antibodies for 60 min. 
After washing, membranes were developed with Clarity™ 
Western ECL Substrate (BioRad, 1705061) and imaged by 
using a Chemi-Doc with a cool CCD camera (Syngene, 
G:BOX Chemi XRQ). Expression was measured by densi-
tometry analysis of the bands using Fiji ImageJ, deducting 
the background intensity, and normalised to the inte-
grated density of the β-actin housekeeping protein band. 
Knockdown efficiency was calculated as test group/con-
trol group x 100%.
To illustrate the distribution of the cell cycle popula-
tion upon exposure to PEI-pSiNPs with MRP1 siRNA, 
cells were analysed using flow cytometry, and a histo-
gram of DNA content plotted. Briefly, the exposed cells 
were trypsinised, PBS rinsed, and fixed dropwise in 100% 
ethanol. The cells in single cells were rinsed and stained 
with PI (50  µg/ml), and subsequently analysed using 
ImageStream flow cytometer (Amnis). Cell populations is 
gated and measured using Amnis software.
Mice tumour model
To assess the siRNA delivery, MRP1 knockdown and 
its subsequent influence on the proliferative state, and 
the effect of knockdown on distal organs, a subcutane-
ous xenograft tumour model was established using nude 
mice. Animal procedures were performed according to a 
protocol approved by South Australian Health & Medical 
Research Institute Animal Ethics Committee (Approval 
number, SAM#98). U87 cells were trypsinised, washed 
with warm PBS and counted. 5 × 106 cells in chilled PBS 
were then mixed 1:1 with Matrigel (E1270, Sigma) to a 
total volume of 100 µl. CD-1 nude mice of mixed gender, 
between 6 and 8 weeks of age, were then subcutaneously 
inoculated with the prepared cells on both flanks. Food 
and water were provided ad  libitum, and since CD-1 
nudes are immunocompromised, they were housed in 
individually-ventilated cages (IVC). On week 4 post-
inoculation, mice bearing tumours reaching 250  mm3 
were paired into groups to receive either pSiNPs/Saline, 
pSiNPs/ctrl siRNA, or pSiNPs/siRNA (MRP1). Each 
group and time point contained at least two mice, each 
bearing (four tumours total per treatment). No statisti-
cal difference in tumour size was observed between the 
groups (data not shown). Each group of mice received 
2 intravenous doses delivered 24  h apart. Each mouse 
received 31.25  mg/kg of pSiNPs loaded with siRNA, 
or the same amount of unloaded pSiNPs, per dose. 
Mice were humanely killed at 24, 72  h post-treatment. 
Tumours, kidneys and duodenums were harvested. For 
histological analysis, tissues were immediately fixed in 
neutral buffered formalin (NBF, Sigma-Aldrich) at 4  °C 
for 2 d, followed by paraffin embedding. For protein level 
analysis, tissues were immediately cut into small cubes, 
1  mm3, immersed in SDS sample buffer, and snap-fro-
zen. For mRNA level analysis, tissues were immersed 
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into RNAlater (AM7023, ThermoFisher) and stored at 
− 20 °C.
Quantitative real time‑polymerase chain reaction 
(qRT‑PCR)
MRP1-mRNA silencing was studied using a BioRad CFX 
Connect QRT-PCR detection system with a SYTO9 rea-
gent to detect the level of MRP1-mRNA expression. In 
summary, tissue sections were homogenised using TRI 
 Reagent® (Sigma-Aldrich) (1  ml per 50–100  mg of tis-
sue). TissueLyser II Qiagen  (QIAGEN®, Hilden, Ger-
many) was used to disrupt and homogenise tissue. Total 
mRNA was extracted using TRI Reagent, according to 
the manufacturer’s protocol. cDNA was synthesised from 
mRNA using M-MLV H (−) reverse transcriptase (Pro-
mega Corporation, Alexandria, NSW, Australia). The 
coincident measurement of the “housekeeping” gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used to control the experimental variations of RNA 
and to normalise the MRP1-mRNA expression data, 
which was calculated using the ΔΔCt method. The prim-
ers were designed via the web tool (http://www.ncbi.nlm.
nih.gov). All primers used for QRT-PCR of MRP1-mRNA 
are shown in Table 1.
Immunohistochemistry
Histological sections were immunohistochemically 
stained to visualise the MRP1 expression and to study 
the proliferative state of the tumours. Microtome sec-
tioned tissue specimens of 5 µm were dehydrated at 50 °C 
overnight, followed by deparaffinisation and rehydration. 
Rehydrated slides were first incubated in sodium cit-
rate buffer pH 6 at 95 °C for 30 min for antigen retrieval 
and cooled down to room temperature. For ki67 stain-
ing, slides were additionally incubated with 0.1% Triton 
X-100 in PBS for 10 min to permeablise the nuclear enve-
lope. Slides were then incubated in 1%  H2O2 for 15 min 
to quench endogenous peroxidase activity, followed 
by serum blocking for 1  h. Goat anti-mouse IgG Fab 
(Abcam, ab6668) was added for 1 h to block endogenous 
IgG. After washing in PBST, slides were incubated with 
primary against ki67 (Abcam, ab8191) or primary against 
MRP1 (Santa Cruz, sc-18835) overnight in a moisture 
chamber at 4  °C. Slides were then incubated with bioti-
nylated mouse-rabbit polyvalent secondary (Abcam, 
ab64264), followed by streptavidin peroxidase (Abcam, 
ab64264) incubation. After washing, slides were devel-
oped using 3,3′-diaminobenzidine (DAB) substrate for 
15  min then counterstained with Mayer’s haematoxylin 
QS (Vector, H-3404), and eventually mounted in cover-
slips with DPX.
Hematoxylin and Eosin (H&E) staining
To study the side-effect of MRP1 knockdown in distal 
organs, kidney and duodenum were excised and sec-
tioned for histological characterisation. Deparaffinised 
and rehydrated sections were stained with Lillie-Mayer’s 
H&E (Australian Biostain P/L) following standard pro-
tocols. H&E and immunohistological stained tissue sec-
tions were imaged using a bright-field microscope.
Statistics
Experiments were conducted in triplicate unless oth-
erwise stated. Error bars presented in charts equal ± 1 
standard deviation (SD). Statistical differences were 
tested by non-parametric Kruskal–Wallis 1-way ANOVA 
test. The hypothesis was accepted at a 95% significant 
level (p < 0.05).
Results
Characteristics of pSiNPs and siRNA release from pSiNPs
pSiNPs were fabricated as a vehicle to deliver siRNA 
for MRP1 silencing. The cellular uptake and biodistri-
bution of the siRNA loaded pSiNP is dependent on the 
size and surface characteristics [34]. Their size, pore 
structure and colloidal stability were characterised by 
means of TEM, dynamic light scattering (DLS), and a 
zeta-potential analyser. TEM images show that plate-
shaped pSiNPs were successfully fabricated at the desired 
size of approximately 110  nm (Fig.  1a). These particles 
contained pores of approximately 15  nm in size. The 
achieved pore dimensions were suitable for loading siR-
NAs, which are approximately 7.5  nm long and 2.5  nm 
wide [35, 36]. Judging from TEM images, there was no 
observable difference in size between PEI-coated and 
non-coated pSiNPs. The hydrodynamic diameter distri-
bution of these particles was further analysed using DLS 
in aqueous media (Fig. 1b). This confirmed that particle 
size distribution was small, where 70% of pSiNP sized 
Table 1 Sequences of  the primers used in  qRT-PCR analy-
sis
Primer ID
MRP1_Human Forward 5′ → AAGGAATGCGCCAAGACTAG → 3′
Reverse 5′ → CCTTAAACAGAGAGGGGTTC → 3′
GAPDH_Human Forward 5′ → GTGAAGGTCGGAGTCAACGG → 3′
Reverse 5′ → TGGAGGGATCTCGCTCCTGG → 3′
MRP1_Mice Forward 5′ → TGCAGAGGCATCTCAGCAACTC → 3′
Reverse 5′ → TTCGGCTATGCTGCTGTGTT → 3′
GAPDH_Mice Forward 5′ → CGACTTCAACAGCAACTCC-
CACTCTTCC → 3′
Reverse 5′ → TGGGTGGTCCAGGGTTTCTTACTC-
CTT → 3′
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between 186 and 198  nm (PDI: 0.12), and 70% of PEI-
pSiNP sized between 169 and 173  nm (PDI: 0.06). The 
PEI-pSiNPs were statistically smaller than the uncoated 
pSiNPs, and this was attributed to the improved colloi-
dal stability of PEI-pSiNPs in an aqueous medium. To 
investigate this phenomenon further, we determined 
the surface zeta potential of pSiNPs. Fabricated pSiNP 
had a slightly negative zeta potential of − 7 mV (Fig. 1c). 
As expected, PEI-capped pSiNPs had an overall posi-
tive charge, with zeta-potential reaching 80 mV. Loading 
with siRNA resulted in both types of particles becoming 
more negatively charged with − 20 and 50 mV in pSiNPs 
and PEI-pSiNPs, respectively. Nanoparticles with a zeta-
potential of more than ± 30 mV are predicted to be col-
loidal stable [37, 38], which explains the higher stability 
of PEI-pSiNPs.
Based on the colloidal stability and the advantage in 
facilitating cellular uptake, we chose PEI-capped pSiNPs 
for further study. siRNA was loaded into pSiNPs and 
capped with PEI, and the loading efficiency was calcu-
lated as 70 ± 9%, effectively carrying 23 µg of siRNA per 
250  µg of PEI-pSiNPs. This loading capacity is much 
higher than pSiNP loading documented without cati-
onic PEI capping, which was only 1.75 µg per 250 µg of 
pSiNPs [16]. The release of siRNA in PBS was followed 
for up to 120 h (Fig. 1d). Substantial siRNA release was 
observed between 24 and 48  h, where 70% siRNA was 
released within this period. The release plateaued from 
72 h onwards. These kinetics indicated a suitable release 
profile that allowed uptake and accumulation of PEI-
pSiNPs in tumours before releasing most of the siRNA 
[39].
Fig. 1 Characterisation of pSiNPs for siRNA delivery. a The structure of pSiNPs and PEI-capped pSiNPs under TEM. b Average hydrodynamic diam-
eter in MilliQ. c Zeta potential of empty pSiNPs and pSiNPs loaded with siRNA. d siRNA release kinetics of PEI-coated pSiNPs. (n = 3; mean ± standard 
deviation; *p < 0.05)
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Intracellular siRNA delivery by pSiNPs
After confirming that the surface chemistry and siRNA 
release profile of PEI-pSiNPs were suitable, pSiNPs were 
fluorescently labelled and exposed to the U87 GBM 
cell line to characterise cellular uptake. As anticipated, 
greater uptake was observed for positively charged 
PEI-capped pSiNPs as compared to uncapped pSiNPs 
(Fig.  2a). Although PEI-capping benefits the loading, 
favourable release profile, and cellular uptake, it is essen-
tial that the nanoparticle delivery by itself is biocompat-
ible to cells. The viability of U87 cells exposed to both 
types of pSiNPs by Trypan Blue exclusion showed no 
significant difference between untreated cells and cells 
exposed to pSiNPs or PEI-pSiNPs (Fig. 2b). This indicate 
that the cytotoxicity of PEI-capped pSiNPs is minimal 
and that these particles are fairly biocompatible.
Fig. 2 Cellular uptake of pSiNPs and subsequent phenotypic changes in U87 GBM cells. a Cellular uptake of fluorescein labelled pSiNPs. Green: 
pSiNPs; red: cytoplasmic mCherry; blue: nucleus. b The viability of U87 cells exposed to pSiNPs measured by Trypan Blue exclusion assay. c MRP1 
expression in U87 cells exposed to siRNA via lipofectamine (Lipo/siRNA) or nanoparticle (pSiNP) delivery by immunoblotting. d Phase contrast 
image of U87 cells exposed to PEI-pSiNPs carrying MRP1 siRNA and untreated at day 3 post-exposure. e The proliferation of U87 cells as measured 
by EdU labelling of cells in S-phase. Green: EdU positive nuclei; Blue: nuclei. f Quantitation of S-phase cell proportions. (*, #, ^, /p < 0.05 as compared to 
untreated, PEI-pSiNPs/ctrl siRNA, PEI-pSiNPs and Lipo/siRNA, respectively)
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In vitro MRP1 silencing
Next, we employed PEI-pSiNPs to deliver MRP1 
siRNA into U87 cells to study downregulation of 
MRP1 via immunoblotting. For comparison, we used 
lipofectamine(Lipo)-based transfection. Results illustrate 
that the MRP1 expression was downregulated in cells 
transfected with MRP1 siRNA as compared to untreated 
controls, with 51 and 30% downregulation in Lipo/siRNA 
(23  µg siRNA) and PEI-pSiNP/siRNA (23  µg siRNA) 
treated cells, respectively (Fig.  2c). In contrast, control 
siRNA delivered via PEI-pSiNPs did not knock down 
MRP1 in U87 cells, ruling out non-specific effects of the 
siRNA and of its delivery system. Additionally, the extent 
of downregulation was dependent on the concentration 
of siRNA delivered as the cells receiving less Lipo/siRNA 
(9  µg) expressed more MRP1 as compared to 23  µg 
delivered via lipofectamine and PEI-pSiNPs (Fig.  2c). 
To demonstrate the effect of MRP1 downregulation by 
PEI-pSiNPs/siRNA on drug efflux, we exposed U87 cells 
to either DOX, or PEI-pSiNPs/siRNA, or co-treatment, 
or left untreated. Result showed that MRP1 silencing 
using PEI-pSiNP/siRNA sensitised U87 cells to DOX 
(Additional file  2: Figure S2). This indicates PEI-pSiNPs 
delivering MRP1 siRNA is a viable approach to reduce 
chemoresistance.
Prolonged culture of U87 cells transfected by PEI-
pSiNPs/siRNA for 2 more days, resulted in an observable 
reduction in total cell population as seen in a representa-
tive phase contrast image (Fig. 2d). However, such effect 
of MRP1 on cancer cell growth has not been well docu-
mented. We speculated that MRP1 knockdown attenu-
ates cell proliferation in parallel to chemosensitisation. 
To quantitatively study cell proliferation, U87 cells trans-
fected with siRNA were pulse-labelled by EdU to identify 
the population of U87 cells that entered S-phase of the 
cell cycle at a given time (Fig. 2e). Significantly less EdU 
positive nuclei were observed in Lipo/siRNA and PEI-
pSiNP/siRNA treated cells as compared to untreated or 
PEI-pSiNP/ctrl siRNA treated cells (Fig.  2f ). Although 
there was also a reduction in proliferation rate in PEI-
pSiNP and PEI-pSiNP/ctrl siRNA treated cells as com-
pared to untreated cells, this effect was not significant 
(p = 0.127). In particular, the EdU proportion of cells 
receiving siRNA delivered by PEI-pSiNPs was sig-
nificantly lower than for cells receiving siRNA in lipo-
fectamine (p = 0.034). Collectively, these results indicate 
a decrease in proliferation rate of GBM cells with MRP1 
knockdown by siRNA, which this effect was independent 
of the siRNA delivery method.
MRP1 functional inhibitor MK‑571
To further elucidate the role of MRP1 in GBM cell pro-
liferation, we exposed them to the functional inhibitor 
MK-571 which attenuates transmembrane transport of 
MRP-specific ligands. Unlike MRP1 siRNA, MK-571 
did not inhibit the translation of MRP1 proteins. It was 
observed that exposure of cells to 25 μM MK-571 was 
sufficient to suppress cell growth without causing cell 
death (Fig.  3a, b). The inhibition of MRP1 transmem-
brane transport by 25 μM MK-571 was assessed by 
monitoring the export of intracellular Calcein AM, a flu-
orescent dye that is a substrate of MRP1, from GBM cells 
[40]. When MRP1 is functionally active in the cell, Cal-
cein AM is exported by MRP1 as an indicator of its trans-
porter function. We observed that the cells treated with 
MK-571 exhibited greater fluorescence signals from Cal-
cein AM than untreated cells, indicating accumulation of 
Calcein-AM as a result of MRP1 inhibition (Fig. 3c, d).
Decrease in proliferation rate and cell cycle arrest
We further studied the proliferation of U87 cells under 
MRP1 silencing by monitoring the expression of Ki67, 
which plays an important role during mitosis, and hence 
serves as a marker for cell proliferation [41]. For all treat-
ment groups, Ki67 expression in the nucleolus and chro-
mosomes was observed during interphase and mitotic 
phase, respectively (Fig. 4a). However, the ratio between 
the Ki67 positive nuclei and the total population of nuclei 
was significantly reduced in Lipo/siRNA and PEI-pSiNP/
siRNA treated U87 cells as compared to untreated con-
trols, but not in PEI-pSiNP/ctrl siRNA (p = 0.275) and 
PEI-pSiNP treated cells (p = 0.127) (Fig. 4b). This is con-
sistent with the observed reduction of EdU labelling and 
confirms that the reduced proliferation rate of U87 cells 
can be attributed to MRP1 knockdown.
This observation prompted us to study the effect of 
MRP1 silencing on cell cycle progression of U87 cells by 
probing the activation of cell cycle regulatory kinases. The 
elevated abundance of phosphorylated cyclin-dependent 
kinases 2 (pCdk2) and histone H3 (pHH3) in U87 cells 
implicate cells arresting at G1/S, and G2/M, respectively 
[42, 43]. By means of Western blot, we observed that the 
abundance of pCdk2 was higher in Lipo/siRNA and PEI-
pSiNPs/siRNA treated U87 cells than for untreated cells 
by a factor of 2 and 1.8, respectively. The abundance of 
pHH3 was similar among the groups (Fig. 4c). Treatment 
with pSiNPs/siRNA and PEI-pSiNPs/ctrl siRNA resulted 
in only a slight pCdk2 elevation as compared to untreated 
cells by a factor of 1.2. Since the inhibitory phosphoryla-
tion on Cdk2 is maximal during G1/S [42], the elevated 
abundance of pCdk2 may suggest that the observed halt 
in proliferation is related to cells arresting at G1/S. A his-
togram of DNA content generated from flow cytometry 
also illustrates an increase in G1 cell population (from 
34 to 56%), and a decrease of G2/M population (from 33 
to 15%) upon MRP1 knockdown via PEI-capped pSiNP 
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siRNA delivery (Fig.  4d). Collectively, the observed cell 
cycle arrest aligns with the results of cell cycle check-
point proteins expression, EdU and Ki67 studies, which 
indicate an obvious reduction in cell proliferation upon 
MRP1 downregulation.
MRP1 knockdown and proliferative state in tumours
The relationship between GBM proliferation and MRP1 
downregulation was further investigated in a tumour 
bearing mouse model. CD-1 nude mice were subcutane-
ously (S.C.) inoculated with U87 cells, and the tumour 
growth kinetics were characterised (data not shown). 
Once the tumours reached a minimum size of 250 mm3, 
mice were treated with PEI-pSiNPs carrying either 
siRNA, ctrl siRNA, or saline intravenously for two con-
secutive days (2 mice and 4 tumours per group). mRNA 
extracted from tumours dissected at selected time 
points was analysed quantitatively for MRP1 expres-
sion. According to qRTPCR data, a reduction of MRP1 
mRNA was observed at 48 and 72 h post-treatment, with 
the greatest reduction being 40% at 48  h (Fig.  5a). The 
expression began to recover between 48 and 72 h, reach-
ing approximately 90% at 72 h. Reduction of MRP1 was 
also observed by immunoblotting at the protein level, 
Fig. 3 Functional inhibition of MRP1 transmembrane transport and GBM cell proliferation. T98G was treated with 25 µM of MK-571 for 72 h and 
untreated cells were used as a control. a The cell viability was measured by the Annexin-V assay and b cells were counted using the Trypan Blue 
assay. c, d At the 24 h time point, cells were incubated in 0.20 µM of Calcein AM staining solution at 37 °C. After incubation for 30 min, cell samples 
were immediately washed and analysed by flow cytometry to determine cellular uptake of Calcein AM. (*p < 0.0329, **p < 0.0023 compared to 
untreated) (n = 4; mean ± standard deviation)
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consistent with gene expression level. The protein expres-
sion of MRP1 in tumours observed at 48 and 72 h post-
treatment with PEI-pSiNPs/siRNA was reduced, by 82 
and 65%, respectively, compared to the levels observed 
in tumours treated with PEI-pSiNPs delivering control 
siRNA (Fig.  5b). This demonstrates that the PEI-pSiNP 
successfully delivered siRNA to the tumour and yielded 
significant MRP1 knockdown.
To further evaluate the siRNA delivery and knockdown 
in  vivo, we histologically compared the MRP1 protein 
distribution in tumours receiving PEI-pSiNPs/siRNA 
and control treatments. Immunohistochemical images 
correspond with qRTPCR and immunoblotting results, 
demonstrating a general downregulation of MRP1 in 
PEI-pSiNP/siRNA treated mice as compared to controls 
(Fig. 5c). Downregulation of MRP1 was also observed in 
mouse epidermis and dermis above the S.C. tumour in 
mice receiving MRP1 siRNA but not in control animals 
(Fig.  5c, arrows). Within the tumours, there was vari-
ation in downregulation of MRP1. Less MRP1 expres-
sion was seen in the GBM cells adjacent to the dermis, 
where blood vessels are abundant, while downregulation 
was less effective on the side adjacent to the peritoneum 
(Fig. 5c, squares). This gradient may reflect the penetra-
tion profile of PEI-pSiNPs into solid tumours.
The use of an untargeted delivery by nanoparticles 
allows investigation of the collateral downregulation of 
MRP1 in distal organs. We harvested kidney and duo-
denum, which also express MRP1 at physiological levels 
[44, 45]. qRT-PCR result suggested that the reduction of 
MRP1 mRNA in the kidney reached as much as 60% at 
48 h post MRP1 siRNA treatment, and 55% (n = 2) at 72 h 
(Fig. 5d). The reduction in the duodenum was even more 
pronounced, being 80% (n = 2) at 48 h, with no recovery 
observed after 72  h post-treatment (Fig.  5e). Therefore, 
we conclude that MRP1 siRNA delivered in non-targeted 
nanoparticles, PEI-pSiNPs in this case, induces MRP1 
knockdown in kidney and duodenum.
Ki67 expression in GBM tumours was also examined 
to study the proliferation potential of GBM cells experi-
encing MRP1 knockdown. Consistent with the in  vitro 
results, Ki67 expression in the tumours of PEI-pSiNP/
siRNA treated mice was reduced compared to controls 
(Fig. 5f ). Such reduction in Ki67 was observed at both 48 
and 72 h post-treatment, indicating that the proliferation 
retardation was sustained after nascent MRP1 mRNA, 
Fig. 4 Effect of MRP1 silencing on the proliferative state of U87 cells. a Immunofluorescence of Ki67 imaged with confocal microscopy. b Quan-
titation of Ki67 positive cell proportion. (*, #, ^p < 0.05 as compared to untreated, PEI-pSiNPs loaded with ctrl siRNA, and PEI-pSiNPs, respectively) (n = 3, 
mean ± standard deviation). c Distribution of cells in G1/S and M phases as indicated by relative expression of phospho-tyr15 Cdk2 and phospho-
ser10 histone H3 revealed by immunoblotting. d Distribution of cell cycle populations as illustrated by DNA content histogram
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and protein levels started to restore. A longer time point 
analysis will be performed in future studies.
Histopathology of MRP1 expressing organs
Since there is no definite conclusion to date as to the 
function of MRP1 in organs physiologically expressing 
MRP1, we performed histopathology analysis on the kid-
ney and duodenum, in which MRP1 was shown to be col-
laterally downregulated, for signs of acute necrosis. The 
histological sections representing 48 h up to 144 h post-
treatment were H&E stained. Histological analysis of kid-
ney was focused on signs of acute tubular necrosis, which 
have been reported for nanotoxicity [46]. There were no 
observable differences between kidneys receiving ctrl-
siRNA and MRP1-siRNA. All of them show no damage 
to endothelial cells, nor was an eosinophilic staining pat-
tern or pyknosis of nuclei observed around proximal and 
distal convoluted tubule (Fig. 5g, arrows), indicating the 
absence of damage to tubular cells [47]. In the duode-
num, we did not observe accumulation of lymphocytes 
in villi of both the controls and MRP1 silenced groups at 
all the time points. Neither did we observe differences in 
the population of goblet cells. These results indicate that 
there was no sign of acute duodenitis [48].
Discussion
MRP1 expression has been identified in a variety of 
tumours and is being comprehensively studied as a thera-
peutic target for chemosensitisation. Various modulators 
have been pursued over the last two decades [11, 12]. 
Fig. 5 Effect of MRP1 silencing in vivo. MRP1 mRNA and protein expression level in tumours of mice being treated with siRNA-loaded PEI-pSiNPs at 
48 and 72 h post-injection (intravenous) as revealed by a qRTPCR (n = 4), b immunoblotting, and c immunohistochemistry. MRP1 mRNA expression 
level in d kidney (n = 2) and e duodenum (n = 2). f Immunohistochemistry of Ki67 expression in the tumour to reveal the proliferative state of U87 
cells in mice receiving different treatments. g H&E staining of kidney and duodenum of mice treated with PEI-pSiNPs with MRP1 siRNA or ctrl siRNA, 
or none, revealing the histopathology of MRP1 downregulation in distal organs over 144 h (6 d) post-injection. (*, #p < 0.05 as compared to controls 
pSiNPs/saline and pSiNPs/ctrl siRNA, respectively)
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Combination therapy has already shown effectiveness 
in  vitro and in  vivo in lung carcinoma [10] and breast 
cancers [49]. Clinical trials exploring MRP1 knockdown 
with a small molecule modulator in patients with breast, 
lung, bowel, melanoma, renal and ovarian cancers are 
ongoing [50].
GBM remains poorly treated, therefore exploring the 
promise and effect of MRP1 downregulation using a 
nanoparticle delivery approach has merit. To date, there 
are only a handful of reports based on in vitro trials. For 
example, patient derived GBM cells were chemosensi-
tised in  vitro using an MRP1 inhibitor [13]. A study by 
Tivnan et  al. tested chemosensitisation with GBM cells 
derived from relapsed patients, demonstrating some 
effectiveness in this setting [8]. Additionally, various 
nanoparticle delivery systems, including ours, have been 
developed to deliver modulators of MRP1 in glioma cells 
[51, 52]. However, in  vivo effectiveness and effects on 
other cells remains to be investigated. Although the cor-
relation between MRP1 expression and more aggressive 
phenotype of cancer has been observed [53], phenotypic 
effects of the knockdown of MRP1 remain unknown.
In this study, we used PEI-capped pSiNPs as a siRNA 
delivery vehicle in vitro and in vivo in order to study the 
knockdown and phenotypic changes, both in tumour 
and collateral organs. The reason for choosing the pSiNP 
delivery vehicle for MRP1 siRNA is due to a number of 
inherent desirable properties including high loading 
capacity, biodegradability and biocompatibility. Further-
more, we have previously documented the successful 
in vitro knockdown of MRP1 with siRNA delivered using 
pSiNPs [16, 23]. The PEI-pSiNPs in this study were of an 
average size of 170 nm, smaller than the average size of 
tumour vasculature ranging from 380 to 780  nm [54]. 
Additionally, nanoparticles at 100 nm range have gener-
ally proven to be long-lasting in the circulation [34]. We 
optimised the release profile for in vivo delivery through 
optimising the pSiNP capping and washing procedure. 
The percentage siRNA released after 24  h was found 
to be only 10%, while 80% of the siRNA was released 
between 24 and 48  h. In view of previous studies that 
have shown PEI nanoparticles, such as JetPEI, to facili-
tate distribution to the respective organs at 24 h [39], we 
believe that the release profile of the PEI-pSiNPs used 
here would prevent immature burst release, and thus 
deliver most of the siRNA into the tissues. As compared 
to other reported nanoparticles of comparable size, chi-
tosan nanoparticles showed siRNA burst release before 
24 h with only 10% siRNA being released between 24 and 
48 h [55], whilst for PLGA nanoparticles release of 50% 
of the loaded amount was reported before 24 h, and only 
10% was released between 24 and 48 h [56].
The superior siRNA retention for the first 24  h is 
thought to be due to the electrostatic interaction between 
PEI and siRNA and the packing of the siRNA into the 
pores of the pSiNPs [57]. The PEI capping also facili-
tated an obvious improvement of cell uptake in GBM 
cells as expected. Whilst the risk of cytotoxicity associ-
ated with branched PEI gene delivery due to the charge 
density has been a concern for clinical translation [58], 
cytotoxicity was not observed with our pSiNP delivery. 
This is consistent with our previous study in terms of a 
lack of observable apoptotic and cytotoxic phenotypes 
[32]. Although the mechanism of such diminished toxic-
ity remains unclear, a similar observation was reported 
by Yuen Shan et al., who evaluated PMMA nanoparticles 
coated with branched 25 kDa PEI for gene delivery and 
showed efficient transfection and low cytotoxicity [59].
MRP1 protein expression was downregulated with 
MRP1 siRNA but not with the scrambled siRNA 
sequence, indicating specific MRP1 effects. While the 
knockdown efficiency of siRNA delivered with lipo-
fectamine (51%± 4%) was observed to be higher than that 
of PEI-pSiNPs (30 ± 9%) in vitro, 30% of downregulation 
was found to be sufficient to sensitise U87 cells to doxo-
rubicin and reduce the viability by 70% as compared to 
exposure to doxorubicin only. While this level of down-
regulation is comparable to our previous in  vitro study 
[16], the delivery vehicle used here did not cause cyto-
toxicity by itself, indicating that it is potentially applicable 
for systemic delivery.
The consistent decrease in total cell counts in MRP1 
siRNA transfected U87 cells, without an increase in 
apoptotic cell death was further investigated. We dem-
onstrated that the proliferation of GBM cells was pro-
portional to MRP1 expression level by means of an EdU 
incorporation assay and Ki67 immunofluorescence, indi-
cating that U87 cells have a much slower proliferation 
rate when MRP1 is silenced. Similar studies of MRP1 
downregulation in neuroblastoma cells using antisense 
expression vectors revealed spontaneous cell death and 
a reduction in cell proliferation [60, 61]. For ovarian car-
cinoma cells, Mahdizadeh et  al. characterised the effect 
of saffron extract-crocin exposure and observed both 
MRP1 silencing, cytotoxicity, and a reduction in cell pro-
liferation [62]. However, the mechanism of the observed 
proliferation retardation in those cancer types was not 
further investigated. In contrast, we observed no glioma 
cell death upon transfection.
Here, the cell cycle arrest at G1/S observed in GBM 
was demonstrated to be associated with MRP1 silencing 
by determining the relative abundance of phosphorylated 
Cdk2 and the increase in G1 cell population. This obser-
vation differs from multidrug transporter P-glycoprotein 
(Pgp) knockdown, which was shown to cause cell cycle 
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arrest at G2/M in leukaemia cells with apoptosis induc-
tion [63]. Since MRP1 and Pgp transport different sub-
strates across the plasma membrane [64], we speculate 
that the effect of MRP1 knockdown on proliferation is 
mediated through the inhibition of transmembrane traf-
ficking. The functional inhibition of MRP1 using MK-571 
also resulting in attenuation of proliferation appears to 
support such speculation.
Since PEI-pSiNP delivery of siRNA is a biocompatible 
and versatile platform, it allowed us to characterise the 
MRP1 knockdown approach and to validate the decrease 
in proliferation of GBM in  vivo. We demonstrated that 
the siRNA delivery resulted in MRP1 downregulation 
at both mRNA and protein level. The observed siRNA-
induced knockdown indicates that the siRNA was deliv-
ered into the cytoplasm where it forms RNA-induced 
silencing complex (RISC) with the complementary 
mRNA before the translation [65]. Hence, it can be con-
cluded that the PEI-pSiNPs successfully accumulated and 
delivered the siRNA into the subcutaneous xenograft 
GBM tumour.
The MRP1 downregulation was observed throughout 
most of the tumour under histological study, indicating 
that the size of PEI-pSiNPs (~ 170 nm) was generally able 
to penetrate the GBM tumour mass and deliver the pay-
load. The penetration of nanoparticles into solid tumour 
depends on the size and surface chemistry of the nano-
particles, and also the architecture of the tumour [66]. 
Although S.C. tumours do not replicate the complexity of 
orthotropic GBM, such as the requirement to transverse 
the BBB, our results serve as the first step translating the 
promise of the MRP1 silencing approach reported based 
on in  vitro studies under GBM-specific in  vivo tumour 
microenvironment. For example, this approach could be 
promising for coating the resected bed of the tumour at 
the completion of surgery and to use an Omaya reservoir 
for MRP1-siRNA delivery to minimise GBM recurrence 
through its anti-proliferative and chemosensitising prop-
erties, since the BBB is not intact at glioblastoma pro-
gression, and at post-surgery [67–69].
For the effectiveness of the delivery to early stage of 
glioma, where the BBB is intact, such approach remains 
to be further optimised and evaluated in suitable ortho-
tropic models.
It has been reported that the expression of Ki67 in brain 
cancers correlates with histological malignancy grade 
in all glioma subtypes [70]. It is also clinically accepted 
that Ki67 generally reflects the cancer aggressiveness, 
as its function is closely linked to cell division [41]. The 
diminished Ki67 positive proportion in tumours of the 
mice receiving PEI-pSiNPs/siRNA indicates that MRP1 
downregulation correlates with GBM proliferation, in 
agreement with the in vitro result. Thus, we believe our 
observations highlight the potential that suppression of 
GBM proliferation associated with MRP1 silencing could 
be exploited to suppress the progression of the residual 
GBM, in parallel to chemosensitising the tumour.
Biodistribution of the cationic nanoparticle is well-
documented to indicate accumulation in the liver, spleen, 
kidney, and lung [71], and both kidney and duodenum 
tissues are known to express MRP1 as their physiological 
phenotype [44, 45]. We observed significant downregula-
tion of MRP1 in these two organs, which was even more 
long-lasting than the silencing in the S.C. GBM tumour, 
which may be due to the expected accumulation profile 
of the non-targeted PEI-pSiNPs. It is reported that the 
physiological function of MRP1 in kidney and diges-
tive system is related to protection from natural tox-
ins, cholehepatic and enterohepatic circulation of bile, 
and in the protection of the biliary tree tissues against 
toxic bile constituents [72]. However, no histopatho-
logical signs that would indicate tissue damage such as 
necrosis in these two organs was observed over 6  days 
post-treatment. Since MRP1 knockdown in tumour and 
proliferation inhibition were observed as early as 48  h 
post-injection and sustained despite nascent mRNA 
started recovering, this may indicate a possible treatment 
window. Future studies should investigate the collateral 
damage of MRP1 siRNA plus cytotoxic drug co-treat-
ments in other organs, such as heart which is susceptible 
to oxidative damage, while MRP1 knockdown would fur-
ther decrease the tolerance in normal organs to cytotoxic 
drugs [73]. In addition, targeted delivery of MRP1 siRNA 
should be explored in follow-up studies to minimise the 
undesired silencing of MRP1 in other organs. Given that 
MRP1 expression also causes radiation resistance, we 
speculate that localised delivery at the site of primary 
tumour resection may provide a means of sensitisation 
towards chemo- and radiotherapy and obviate the need 
for systemic exposure and potential toxicity from MRP1 
downregulation in other organs.
This study highlights the relationship between MRP1 
and GBM cell proliferation, and provides insights into 
the relationship between MRP1 expression and malig-
nancy grade. In addition, we demonstrated that MRP1 
silencing by employing PEI-pSiNP delivery of siRNA 
alone would reduce the proliferation rate of GBM cells 
by attenuating the cell cycle at G1/S, without cytotoxic 
drug co-treatment, indicating the importance of MRP1 
expression in the biology of GBM. Since the effect of 
siRNA subsides over time mainly due to the dilution of 
intracellular siRNA owing to cell division [74], the pro-
liferation attenuation effect associated with MRP1 silenc-
ing may intensify the therapeutic effect of this approach. 
MRP1 knockdown of GBM was demonstrated here for 
the first time in  vivo, and the proliferation attenuation 
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was also observed in the tumour, highlighting the prom-
ise of MRP1 as a treatment to GBM.
Conclusion
Chemoresistance in GBM, partially mediated by MRP1 
overexpression in the brain, renders GBM a fatal disease 
that is notoriously difficult to eradicate. Gene therapy 
aimed at MRP1 silencing has been showing promising 
results in sensitising other drug-resistant cancers while 
its effect on brain cancers have not been thoroughly 
investigated. Here, we demonstrated that the MRP1 
silencing using pSiNP-based delivery of MRP1 siRNA 
not only drug-sensitised, but also inhibited GBM cell 
proliferation by arresting cell cycle at G1/S on its own. 
The reduction in proliferation rate was independent of 
the siRNA delivery method. This effect may be medi-
ated via transmembrane transporters as suggested by 
a MRP1 functional inhibition assay. Through the use of 
PEI-capped pSiNP delivery of siRNA, we established 
MRP1 silencing in GBM tumours in mice. Consistently, 
the reduction of ki67 positive staining in GBM correlated 
with MRP1 silencing in the tumour. MRP1 siRNA deliv-
ery was not targeted to tumours and hence also showed 
silencing in MRP1-expressing organs such as kidney and 
duodenum. However, no histopathological signs were 
observed. In conclusion, this study illustrated, for the 
first time, the correlations between MRP1 expression and 
GBM proliferation. This provides insights into residual 
GBM eradication through highlighting the potential that, 
apart from chemotherapeutics sensitising, MRP1 silenc-
ing itself may deliver therapeutic effects by attenuating 
the growth of GBM.
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